Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

Core Points - Nanobiotix is a late-stage clinical biotechnology company focused on nanoparticle-based treatments for cancer and other major diseases [1][2] - The company will participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, with a live webcast available [1] - Nanobiotix is headquartered in Paris, France, and is listed on Euronext Paris and NASDAQ [3] Company Overview - Nanobiotix was incorporated in 2003 and has been listed on Euronext Paris since 2012 and on NASDAQ since December 2020 [3] - The company holds over 25 umbrella patents related to three nanotechnology platforms, focusing on oncology, bioavailability, and central nervous system disorders [4] Contact Information - For media inquiries, the company has designated contacts in both France and globally [5]